Amarin Corp Plc (AMRN)

[ziploc_1]

ILT...QUOTE..."On June 12, 2018, Amarin announced that it had entered into a collaboration agreement with Mochida Pharmaceutical Co., Ltd. (“Mochida”), an
integrated Japanese pharmaceutical company. The collaboration agreement is focused on the development and commercialization of early-stage drug products
based on omega-3 acid EPA (eicosapentaenoic acid). Under the collaboration agreement Amarin will, among other things, obtain an exclusive license to
certain Mochida technology to develop, manufacture and commercialize new drug products that contain high purity EPA for the United States and other
territories. Under the collaboration agreement, Amarin will pay Mochida anon-refundable, non-creditable upfront payment of $2.7 million, and 'MAY BE'
obligated to pay milestone payments and royalties on net sales of future products arising from the collaboration, if any."

Vascepa had been commercialized by Amarin prior to the 2018 agreement with Mochida..I was always under the impression that Amarin had paid Mochida $2.7 million in lieu of royalties on sales of Vascepa..If you have information to the contrary, I would appreciate you posting it.